Seroprevalence of hepatitis B and C in type 2 diabetic patients

Hua Fen Chen, Chung-Yi Li, Peter Chen, Ting Ting See, Hsin Yu Lee

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Background: Many reports in the literature suggest that chronic hepatitis C virus (HCV) infection is associated with diabetes, but the results are conflicting. The aim of our study was to investigate the seroprevalence of hepatitis B virus (HBV) and HCV infections in type 2 diabetes mellitus (DM) patients. Methods: We collected 820 consecutive type 2 diabetic patients attending 2 of 5 outpatient endocrinology clinics in Far Eastern Memorial Hospital from March to July 2003. The control group consisted of 905 subjects who came for medical check-ups at the Family Medicine Department. We determined hepatitis B surface antigen (HBsAg) and anti-HCV in both groups, using third-generation microparticle enzyme immunoassay. Results: No significant difference was found between type 2 DM patients and the control group for seropositivity of HBsAg (13.5% versus 12.4%; odds ratio [OR] = 1.09; 95% confidence interval [CI]: 0.77-1.55; p = 0.441), but anti-HCV seropositivity was detected in 6.8% of patients and 2.6% of the control subjects (OR = 2.87; 95% CI: 1.51-5.46; p < 0.001). In anti-HCV-positive DM patients, abnormal alanine aminotransferase was observed in 61.8%, compared with only 34.2% of anti-HCV-negative DM patients (p < 0.001). We did not observe any difference in risk factors for HCV infection between anti-HCV-positive and -negative DM patients. Conclusion: The rate of seropositive anti-HCV is 2.8 times higher in type 2 DM patients than non-diabetic control subjects.

Original languageEnglish
Pages (from-to)146-152
Number of pages7
JournalJournal of the Chinese Medical Association
Volume69
Issue number4
DOIs
Publication statusPublished - 2006 Jan 1

Fingerprint

Seroepidemiologic Studies
Hepatitis C
Hepatitis B
Hepacivirus
Virus Diseases
Type 2 Diabetes Mellitus
Diabetes Mellitus
Hepatitis B Surface Antigens
Odds Ratio
Confidence Intervals
Control Groups
Endocrinology
Chronic Hepatitis C
Ambulatory Care Facilities
Alanine Transaminase
Immunoenzyme Techniques
Hepatitis B virus
Medicine

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Chen, Hua Fen ; Li, Chung-Yi ; Chen, Peter ; See, Ting Ting ; Lee, Hsin Yu. / Seroprevalence of hepatitis B and C in type 2 diabetic patients. In: Journal of the Chinese Medical Association. 2006 ; Vol. 69, No. 4. pp. 146-152.
@article{ca0fda5190d84b92a19d80b5af739b33,
title = "Seroprevalence of hepatitis B and C in type 2 diabetic patients",
abstract = "Background: Many reports in the literature suggest that chronic hepatitis C virus (HCV) infection is associated with diabetes, but the results are conflicting. The aim of our study was to investigate the seroprevalence of hepatitis B virus (HBV) and HCV infections in type 2 diabetes mellitus (DM) patients. Methods: We collected 820 consecutive type 2 diabetic patients attending 2 of 5 outpatient endocrinology clinics in Far Eastern Memorial Hospital from March to July 2003. The control group consisted of 905 subjects who came for medical check-ups at the Family Medicine Department. We determined hepatitis B surface antigen (HBsAg) and anti-HCV in both groups, using third-generation microparticle enzyme immunoassay. Results: No significant difference was found between type 2 DM patients and the control group for seropositivity of HBsAg (13.5{\%} versus 12.4{\%}; odds ratio [OR] = 1.09; 95{\%} confidence interval [CI]: 0.77-1.55; p = 0.441), but anti-HCV seropositivity was detected in 6.8{\%} of patients and 2.6{\%} of the control subjects (OR = 2.87; 95{\%} CI: 1.51-5.46; p < 0.001). In anti-HCV-positive DM patients, abnormal alanine aminotransferase was observed in 61.8{\%}, compared with only 34.2{\%} of anti-HCV-negative DM patients (p < 0.001). We did not observe any difference in risk factors for HCV infection between anti-HCV-positive and -negative DM patients. Conclusion: The rate of seropositive anti-HCV is 2.8 times higher in type 2 DM patients than non-diabetic control subjects.",
author = "Chen, {Hua Fen} and Chung-Yi Li and Peter Chen and See, {Ting Ting} and Lee, {Hsin Yu}",
year = "2006",
month = "1",
day = "1",
doi = "10.1016/S1726-4901(09)70195-9",
language = "English",
volume = "69",
pages = "146--152",
journal = "Journal of the Chinese Medical Association",
issn = "1726-4901",
publisher = "Elsevier Taiwan LLC",
number = "4",

}

Seroprevalence of hepatitis B and C in type 2 diabetic patients. / Chen, Hua Fen; Li, Chung-Yi; Chen, Peter; See, Ting Ting; Lee, Hsin Yu.

In: Journal of the Chinese Medical Association, Vol. 69, No. 4, 01.01.2006, p. 146-152.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Seroprevalence of hepatitis B and C in type 2 diabetic patients

AU - Chen, Hua Fen

AU - Li, Chung-Yi

AU - Chen, Peter

AU - See, Ting Ting

AU - Lee, Hsin Yu

PY - 2006/1/1

Y1 - 2006/1/1

N2 - Background: Many reports in the literature suggest that chronic hepatitis C virus (HCV) infection is associated with diabetes, but the results are conflicting. The aim of our study was to investigate the seroprevalence of hepatitis B virus (HBV) and HCV infections in type 2 diabetes mellitus (DM) patients. Methods: We collected 820 consecutive type 2 diabetic patients attending 2 of 5 outpatient endocrinology clinics in Far Eastern Memorial Hospital from March to July 2003. The control group consisted of 905 subjects who came for medical check-ups at the Family Medicine Department. We determined hepatitis B surface antigen (HBsAg) and anti-HCV in both groups, using third-generation microparticle enzyme immunoassay. Results: No significant difference was found between type 2 DM patients and the control group for seropositivity of HBsAg (13.5% versus 12.4%; odds ratio [OR] = 1.09; 95% confidence interval [CI]: 0.77-1.55; p = 0.441), but anti-HCV seropositivity was detected in 6.8% of patients and 2.6% of the control subjects (OR = 2.87; 95% CI: 1.51-5.46; p < 0.001). In anti-HCV-positive DM patients, abnormal alanine aminotransferase was observed in 61.8%, compared with only 34.2% of anti-HCV-negative DM patients (p < 0.001). We did not observe any difference in risk factors for HCV infection between anti-HCV-positive and -negative DM patients. Conclusion: The rate of seropositive anti-HCV is 2.8 times higher in type 2 DM patients than non-diabetic control subjects.

AB - Background: Many reports in the literature suggest that chronic hepatitis C virus (HCV) infection is associated with diabetes, but the results are conflicting. The aim of our study was to investigate the seroprevalence of hepatitis B virus (HBV) and HCV infections in type 2 diabetes mellitus (DM) patients. Methods: We collected 820 consecutive type 2 diabetic patients attending 2 of 5 outpatient endocrinology clinics in Far Eastern Memorial Hospital from March to July 2003. The control group consisted of 905 subjects who came for medical check-ups at the Family Medicine Department. We determined hepatitis B surface antigen (HBsAg) and anti-HCV in both groups, using third-generation microparticle enzyme immunoassay. Results: No significant difference was found between type 2 DM patients and the control group for seropositivity of HBsAg (13.5% versus 12.4%; odds ratio [OR] = 1.09; 95% confidence interval [CI]: 0.77-1.55; p = 0.441), but anti-HCV seropositivity was detected in 6.8% of patients and 2.6% of the control subjects (OR = 2.87; 95% CI: 1.51-5.46; p < 0.001). In anti-HCV-positive DM patients, abnormal alanine aminotransferase was observed in 61.8%, compared with only 34.2% of anti-HCV-negative DM patients (p < 0.001). We did not observe any difference in risk factors for HCV infection between anti-HCV-positive and -negative DM patients. Conclusion: The rate of seropositive anti-HCV is 2.8 times higher in type 2 DM patients than non-diabetic control subjects.

UR - http://www.scopus.com/inward/record.url?scp=33646253204&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646253204&partnerID=8YFLogxK

U2 - 10.1016/S1726-4901(09)70195-9

DO - 10.1016/S1726-4901(09)70195-9

M3 - Article

C2 - 16689194

AN - SCOPUS:33646253204

VL - 69

SP - 146

EP - 152

JO - Journal of the Chinese Medical Association

JF - Journal of the Chinese Medical Association

SN - 1726-4901

IS - 4

ER -